BiomX Inc., a clinical-stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from dysbiosis of the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases, primary sclerosing cholangitis, and cancer. The company is based in Ness Ziona, Israel.